Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb Study to Investigate PD-0325901 as Monotherapy for Neurofibromatosis Type 1 Patients with Plexiform Neurofibromas

Trial Profile

A Phase IIb Study to Investigate PD-0325901 as Monotherapy for Neurofibromatosis Type 1 Patients with Plexiform Neurofibromas

Planning
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2018

At a glance

  • Drugs PD 325901 (Primary)
  • Indications Neurofibromatoses; Plexiform neurofibroma
  • Focus Therapeutic Use
  • Sponsors SpringWorks Therapeutics
  • Most Recent Events

    • 05 Nov 2018 According to a SpringWorks Therapeutics media release, this trial will be initiated in the first half of 2019.
    • 18 Sep 2018 New trial record
    • 05 Sep 2018 According to a BeiGene media release, SpringWorks Therapeutics plans to initiate this trial in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top